NDC product
Cholestyramine
NDC 51224-011 · TAGI Pharma, Inc.
Key facts
| Product NDC | 51224-011 |
|---|---|
| Proprietary name | Cholestyramine |
| Nonproprietary name | Cholestyramine |
| Substances | CHOLESTYRAMINE |
| Dosage form | POWDER, FOR SUSPENSION |
| Route | ORAL |
| Labeler | TAGI Pharma, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA209597 |
| Pharmacologic classes | Bile Acid Sequestrant [EPC], Bile-acid Binding Activity [MoA] |
| Marketing start | Mar 10, 2021 |
| Marketing end | Nov 30, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory